Quantedge Capital Fully Exits Supernus Pharmaceuticals Stake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 45 minutes ago
0mins
Should l Buy SUPN?
Source: Fool
- Complete Exit: Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals in Q1 2026, with an estimated transaction value of $4.56 million, resulting in a net position value decrease of $4.45 million, indicating a cautious outlook on the company's future prospects.
- Significant Revenue Growth: Supernus Pharmaceuticals reported a 39% increase in Q1 revenue to $207.7 million, driven by rapid expansion of newer growth products, particularly with key products like Qelbree and GOCOVRI seeing a 56% revenue increase, showcasing the company's competitive position in the market.
- Enhanced Financial Flexibility: As of the end of Q1 2026, Supernus held approximately $384 million in cash and marketable securities, providing the company with the flexibility to continue investing in pipeline development and commercialization, reflecting a robust financial status in facing market challenges.
- Reduced Market Dependence: Supernus is decreasing its reliance on older epilepsy drugs, with Qelbree sales rising 20% to $77.9 million, while collaboration revenue from the Biogen-partnered ZURZUVAE contributed an additional $27.6 million, indicating a successful transition towards new product offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUPN
Wall Street analysts forecast SUPN stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 49.370
Low
55.00
Averages
61.33
High
65.00
Current: 49.370
Low
55.00
Averages
61.33
High
65.00
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. It is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantedge Capital Fully Exits Supernus Pharmaceuticals Stake
- Complete Exit: Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals in Q1 2026, with an estimated transaction value of $4.56 million, resulting in a net position value decrease of $4.45 million, indicating a cautious outlook on the company's future prospects.
- Significant Revenue Growth: Supernus Pharmaceuticals reported a 39% increase in Q1 revenue to $207.7 million, driven by rapid expansion of newer growth products, particularly with key products like Qelbree and GOCOVRI seeing a 56% revenue increase, showcasing the company's competitive position in the market.
- Enhanced Financial Flexibility: As of the end of Q1 2026, Supernus held approximately $384 million in cash and marketable securities, providing the company with the flexibility to continue investing in pipeline development and commercialization, reflecting a robust financial status in facing market challenges.
- Reduced Market Dependence: Supernus is decreasing its reliance on older epilepsy drugs, with Qelbree sales rising 20% to $77.9 million, while collaboration revenue from the Biogen-partnered ZURZUVAE contributed an additional $27.6 million, indicating a successful transition towards new product offerings.
See More
Supernus Pharmaceuticals CEO to Attend Healthcare Conference
- Conference Participation: Jack A. Khattar, CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026, at 3:40 p.m. PT in Las Vegas, showcasing the company's advancements in treating central nervous system diseases.
- Investor Engagement: Investors interested in meeting with company management during the conference can contact the Bank of America conference coordinator, enhancing communication and collaboration opportunities with stakeholders.
- Live Webcast: The presentation will be accessible via a live audio webcast on Supernus Pharmaceuticals' website, with an archived replay available for 60 days post-conference, ensuring that investors who cannot attend live can still access critical information.
- Product Portfolio: Supernus Pharmaceuticals focuses on treatments for CNS diseases, with a diverse portfolio including approved therapies for ADHD and Parkinson's disease-related dyskinesia, demonstrating the company's broad influence and market potential in the biopharmaceutical sector.
See More
Supernus Pharmaceuticals Q1 2026 Earnings Highlights
- Significant Revenue Growth: Supernus reported total revenues of $207.7 million for Q1 2026, reflecting a 39% year-over-year increase, with growth products seeing a remarkable 56% rise, indicating strong market performance and sustained product demand.
- ONAPGO Sales Outlook: ONAPGO generated net sales of $8.4 million in Q1, with regulatory submission to the FDA expected in Q3 2026, and potential market launch before mid-2027, which could provide a new revenue stream for the company.
- Strong ZURZUVAE Performance: ZURZUVAE contributed $27.6 million in collaboration revenues in Q1, with 85% of prescriptions coming from repeat prescribers, demonstrating high market acceptance and helping to solidify the company's market position.
- Enhanced Financial Flexibility: As of March 31, 2026, Supernus had approximately $384 million in cash and cash equivalents with no debt, providing significant financial flexibility for potential M&A and other growth opportunities in the future.
See More
Supernus Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Report: Supernus Pharmaceuticals reported a Q1 GAAP EPS of -$0.04, missing expectations by $0.03, indicating challenges in profitability despite revenue growth.
- Revenue Growth: The company achieved Q1 revenue of $207.7 million, a 38.6% year-over-year increase, exceeding market expectations by $14.78 million, reflecting strong product demand and market performance.
- 2026 Financial Guidance: Supernus projects GAAP operating earnings for 2026 to range from $0 to $30 million, with adjusted operating earnings expected between $140 million and $170 million, showcasing confidence in future growth.
- Asset Acquisition: Supernus finalized a $350 million acquisition of Navitor’s SPN-820 assets, which will enhance its product portfolio and drive long-term growth.
See More
Supernus Pharmaceuticals to Announce Q1 Earnings on May 5
- Earnings Announcement: Supernus Pharmaceuticals is set to release its Q1 2023 earnings on May 5 after market close, with a consensus EPS estimate of $0.28, reflecting a substantial year-over-year increase of 233.3%, indicating a significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $192.92 million, representing a 28.7% year-over-year growth, which highlights Supernus's positive performance in market demand and product sales, potentially leading to a favorable impact on stock prices.
- Historical Performance Review: Over the past year, Supernus has not missed EPS estimates, achieving a 0% miss rate, while it has successfully met revenue estimates 75% of the time, indicating a high reliability in revenue forecasting that boosts investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced two upward and four downward revisions, reflecting mixed market sentiments regarding Supernus's future performance, which may influence investor decisions.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
Quantedge Capital Fully Exits Supernus Pharmaceuticals Stake
- Complete Exit: Quantedge Capital sold all 89,600 shares of Supernus Pharmaceuticals in Q1 2026, with an estimated transaction value of $4.56 million, resulting in a net position value decrease of $4.45 million, indicating a cautious outlook on the company's future prospects.
- Significant Revenue Growth: Supernus Pharmaceuticals reported a 39% increase in Q1 revenue to $207.7 million, driven by rapid expansion of newer growth products, particularly with key products like Qelbree and GOCOVRI seeing a 56% revenue increase, showcasing the company's competitive position in the market.
- Enhanced Financial Flexibility: As of the end of Q1 2026, Supernus held approximately $384 million in cash and marketable securities, providing the company with the flexibility to continue investing in pipeline development and commercialization, reflecting a robust financial status in facing market challenges.
- Reduced Market Dependence: Supernus is decreasing its reliance on older epilepsy drugs, with Qelbree sales rising 20% to $77.9 million, while collaboration revenue from the Biogen-partnered ZURZUVAE contributed an additional $27.6 million, indicating a successful transition towards new product offerings.
See More
Supernus Pharmaceuticals CEO to Attend Healthcare Conference
- Conference Participation: Jack A. Khattar, CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Healthcare Conference on May 12, 2026, at 3:40 p.m. PT in Las Vegas, showcasing the company's advancements in treating central nervous system diseases.
- Investor Engagement: Investors interested in meeting with company management during the conference can contact the Bank of America conference coordinator, enhancing communication and collaboration opportunities with stakeholders.
- Live Webcast: The presentation will be accessible via a live audio webcast on Supernus Pharmaceuticals' website, with an archived replay available for 60 days post-conference, ensuring that investors who cannot attend live can still access critical information.
- Product Portfolio: Supernus Pharmaceuticals focuses on treatments for CNS diseases, with a diverse portfolio including approved therapies for ADHD and Parkinson's disease-related dyskinesia, demonstrating the company's broad influence and market potential in the biopharmaceutical sector.
See More
Supernus Pharmaceuticals Q1 2026 Earnings Highlights
- Significant Revenue Growth: Supernus reported total revenues of $207.7 million for Q1 2026, reflecting a 39% year-over-year increase, with growth products seeing a remarkable 56% rise, indicating strong market performance and sustained product demand.
- ONAPGO Sales Outlook: ONAPGO generated net sales of $8.4 million in Q1, with regulatory submission to the FDA expected in Q3 2026, and potential market launch before mid-2027, which could provide a new revenue stream for the company.
- Strong ZURZUVAE Performance: ZURZUVAE contributed $27.6 million in collaboration revenues in Q1, with 85% of prescriptions coming from repeat prescribers, demonstrating high market acceptance and helping to solidify the company's market position.
- Enhanced Financial Flexibility: As of March 31, 2026, Supernus had approximately $384 million in cash and cash equivalents with no debt, providing significant financial flexibility for potential M&A and other growth opportunities in the future.
See More
Supernus Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Report: Supernus Pharmaceuticals reported a Q1 GAAP EPS of -$0.04, missing expectations by $0.03, indicating challenges in profitability despite revenue growth.
- Revenue Growth: The company achieved Q1 revenue of $207.7 million, a 38.6% year-over-year increase, exceeding market expectations by $14.78 million, reflecting strong product demand and market performance.
- 2026 Financial Guidance: Supernus projects GAAP operating earnings for 2026 to range from $0 to $30 million, with adjusted operating earnings expected between $140 million and $170 million, showcasing confidence in future growth.
- Asset Acquisition: Supernus finalized a $350 million acquisition of Navitor’s SPN-820 assets, which will enhance its product portfolio and drive long-term growth.
See More
Supernus Pharmaceuticals to Announce Q1 Earnings on May 5
- Earnings Announcement: Supernus Pharmaceuticals is set to release its Q1 2023 earnings on May 5 after market close, with a consensus EPS estimate of $0.28, reflecting a substantial year-over-year increase of 233.3%, indicating a significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $192.92 million, representing a 28.7% year-over-year growth, which highlights Supernus's positive performance in market demand and product sales, potentially leading to a favorable impact on stock prices.
- Historical Performance Review: Over the past year, Supernus has not missed EPS estimates, achieving a 0% miss rate, while it has successfully met revenue estimates 75% of the time, indicating a high reliability in revenue forecasting that boosts investor confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced two upward and four downward revisions, reflecting mixed market sentiments regarding Supernus's future performance, which may influence investor decisions.
See More
Alpha Cognition Appoints New Board Member
- New Board Appointment: Alpha Cognition has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bringing decades of leadership experience in the pharmaceutical and biotechnology sectors, which is expected to significantly aid the company's commercial launch of ZUNVEYL and the development of its sublingual program.
- Financial and Strategic Expertise: Sensenig previously served as CFO at Radius Health, where she played a crucial role in driving growth and financial performance, and her extensive experience is anticipated to enhance Alpha Cognition's operational efficiency and financial health in the competitive biopharmaceutical market.
- Board Transition: Len Mertz has informed the company that he will not seek re-election to the Board, and as a founding member, he provided valuable leadership in advancing the company to public markets and progressing its pipeline, with management expressing gratitude for his contributions.
- Future Outlook: Alpha Cognition is dedicated to developing treatments for neurodegenerative diseases, with ZUNVEYL being a novel drug for Alzheimer's disease, expected to carve out a niche in the market due to its unique mechanism of action and minimal side effects.
See More
